Arteriosclerosis Obliterans Market Shows Promising Growth Prospects During the Forecast Period (2026-2036) Amid Evolving Treatment Landscape | DelveInsight

The arteriosclerosis obliterans treatment market across the seven major markets is forecast to grow through 2036, driven by rising PAD risk factors, improved diagnosis, and demand for treatments that may reduce amputation risk. The report highlights pipeline candidates including Nippon Shinyaku’s selexipag, in Phase III development in Japan, alongside orforglipron, CLBS12 and other therapies; however, disease-modifying drug options remain limited and selexipag lacks definitive clinical outcome trials in PAD.

Analysis

This is a market-research forecast, not evidence of a near-term change in prescribing or revenue; its optimistic market-growth framing should not be capitalized into broad pharma/device estimates. The key equity exposure is concentrated in clinical execution: Lisata Therapeutics (LSTA) has direct pipeline relevance through CLBS12, while Regeneron (REGN) is named for candidates but the article provides no trial detail establishing meaningful PAD revenue potential. Orforglipron’s metabolic rationale may lower vascular risk over time, but it is not equivalent to demonstrated limb or walking benefit; any read-through to Eli Lilly (LLY) is premature. Selexipag’s PAH experience does not establish efficacy in PAD, and a Japan Phase III result is the more relevant discrete catalyst.

Over 1–3 months, this release itself offers little fundamental catalyst. Over 6–18 months, trial endpoints, safety, regulatory progress, and reimbursement—not prevalence forecasts—determine value. A successful symptom therapy could expand treated demand and complement interventions; regenerative approaches could compete for patients with advanced ischemia, but neither is shown here to displace angioplasty, stents, or established risk management. Devices from Abbott (ABT), Boston Scientific (BSX), and Medtronic (MDT) therefore have no clear negative read-through absent evidence of procedure substitution. The contrarian point: a large epidemiologic pool does not guarantee a commercially addressable market when diagnosis, trial endpoint relevance, adoption, and access remain uncertain. Falsify the cautious view with reproducible clinically meaningful PAD outcomes and a credible launch/access pathway; negative trials or no movement toward those milestones leave the forecast as TAM narrative.

Key Decisions for Investors

• No broad sector trade on this release; treat its positive sentiment as informational rather than an earnings revision. Verify the underlying trial registry, phase, endpoints, and current status for each named asset before updating forecasts.
• Keep LSTA on a catalyst watchlist, not an automatic long: CLBS12 is a direct but clinical-risk exposure. Reassess only against independently reported efficacy, safety, enrollment, and funding/runway data; a failed or delayed study is the principal downside trigger.
• For REGN and LLY, do not assign material PAD value from this article. Track whether REGN’s named candidates are actually being developed for this indication and whether orforglipron has PAD-specific outcome evidence; absent that, their PAD read-through is likely immaterial relative to company-wide drivers.
• Monitor Nippon Shinyaku’s Japan Phase III selexipag data as the clearest stated near-term disease-specific catalyst. Look for walking-function and safety results, then regulatory and reimbursement steps; PAH commercial history alone is not a buy signal.